CYP1B1 has been found to have an effect on tumor response to anticancer drugs, such as cyclophosphamide, PTX and DTX, which consequently affects pharmacokinetics and the therapeutic efficacy of the drugs (8,22,23). Here, CYP1B1 is linked to neoplasm.